Abstract

Abstract Uveal melanoma (UM) arises from melanocytes of the uveal tract in the eye and is the most common intraocular malignancy in adults. Primary UM lesions often harbor mutations in G-proteins, GNAQ or GNA11, and are successfully treated by radiotherapy or enucleation. However, 50% of patients develop metastases. Of these metastatic UM (MUM) patients, 80%develop metastases to the liver, an effect strongly correlated with the loss of function of BAP1,a nuclear deubiquitinase. BAP1-mutant MUMs are less responsive to conventional treatments, such as chemotherapy and immune checkpoint inhibitors, with 50% of these patients having an overall survival of only 1 year. We propose that the unique metabolic intermediates found in liver microenvironment may dictate MUM tropism, aggressiveness, and poor therapeutic response. Here, using a combination of in vitro and ex vivo liver slice cultures, we found that the liver microenvironment induces gene expression alterations consistent with limiting the toxicity of reactive oxygen species (ROS). Importantly, we note that mutant BAP1 UM displayed improved ROS detoxification compared to its wildtype counterparts. Furthermore, publicly available datasets suggest patients with mutant BAP1 UM, the subset of patients with liver metastases, have corresponding ROS detoxification gene expression patterns. These findings suggest that the liver microenvironment and BAP1 loss directs MUM to mitigate ROS-associated toxicity. This compensatory mechanism may be therapeutically exploited and pair well as a combination treatment with the recently approved bispecific agent, Tebentafusp, to selectively target liver MUM. Citation Format: Camille J. Cunanan. Exploiting ferroptosis in mutant BAP1 uveal melanoma. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6152.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call